BioSpace News Archive

The global clinical workflow solutions market size accounted for USD 9.27 billion in 2022 and is expected to surpass around USD 23.99 billion by 2030, growing at a CAGR of 12.6% from 2022 to 2030.

Calgary-based genomics and precision health company, BioAro, is launching its comprehensive genetic and microbiome testing services.

AustinPx, Pharmaceutics and Manufacturing, a contract development and manufacturing organization, announced the appointment of Derek Hennecke and Marshall Crew as independent members of its board of directors.

Bright Peak Therapeutics announced the formation of a Scientific Advisory Board comprised of world-renowned experts in immuno-oncology basic, translational and clinical research.

Sientra, Inc., a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of common stock.

Origin Therapeutics Holdings Inc.(CSE: ORIG) (the “Company”, “Origin Therapeutics” or “Origin”) today announced that one of its portfolio companies, Clairvoyant Therapeutics (“Clairvoyant”), has received regulatory approval from the Finnish Medicines Agency (FIMEA) to proceed with the company’s Phase 2 clinical trial investigating psilocybin for the treatment of alcohol use disorder (AUD) in Finland.

Radiopharm Theranostics is pleased to announce that Imperial College London’s F-18 Pivalate has achieved successful Phase 2a data in patients with brain metastases, having shown significant tumour uptake that was consistent and independent from the tumour origin.

According to Nova one advisor, the global Artificial Intelligence (AI) in Life Sciences market size is expected to hit around USD 6.20 billion by 2030 from valued at USD 1.9 billion in 2021 and growing at a CAGR of 20.4% from 2022 to 2030.

According to Nova one advisor, the global Cancer Gene Therapy market size was valued at USD 2.8 billion in 2021 and is predicted to hit USD 9.7 billion by 2030 with a registered CAGR of 20.9% during the forecast period 2022 to 2030.

According to Nova one advisor, the global Artificial Intelligence (AI) in Healthcare market size was valued at USD 11.09 billion in 2021 and is predicted to hit USD 208.9 billion by 2030 with a registered CAGR of 38.9% during the forecast period 2022 to 2030.